as of 10-08-2026 2:10pm EST
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
| Founded: | 2012 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 582.2M | IPO Year: | 2021 |
| Target Price: | $12.25 | AVG Volume (30 days): | 21.9K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $4.75 - $12.18 | Next Earning Date: | 11-12-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -13.54% | Revenue Growth (next year): | 87.65% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
See how VALN stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "VALN Valneva SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.